Skip to main content

Table 5 Association of therapeutic response and pulmonary function change

From: Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation

 

No-response group

Response group

P-value

BOS diagnosis

 FVC (% predicted)

72.27 ± 15.42

73.19 ± 12.87

.838

 FEV1 (% predicted)

56.46 ± 16.05

56.73 ± 15.52

.959

 FEV1/FVC (%)

63.64 ± 10.54

63.83 ± 16.29

.970

 RV (% predicted)

103.50 ± 39.10

116.68 ± 35.88

.307

 TLC (% predicted)

82.30 ± 11.58

90.57 ± 12.07

.054

 RV/TLC (%)

37.80 ± 10.76

40.93 ± 9.59

.366

 DLCO (% predicted)

58.40 ± 21.81

63.30 ± 16.49

.429

Pre-HSCT – BOS diagnosisa

 Δ FVC (% predicted)

12.45 ± 13.28

23.59 ± 15.88

.036

 Δ FEV1 (% predicted)

30.81 ± 18.16

40.61 ± 18.89

.126

 Δ FEV1/FVC (%)

18.18 ± 12.78

14.46 ± 15.63

.467

 Δ RV (% predicted)

−20.20 ± 32.45

−36.63 ± 35.90

.194

 Δ TLC (% predicted)

3.90 ± 13.85

3.63 ± 11.25

.948

 Δ RV/TLC (%)

−9.90 ± 7.69

−14.08 ± 10.17

.232

 Δ DLCO (% predicted)

−1.00 ± 20.75

−0.51 ± 16.73

.937

  1. aFour missing values in Pre-HSCT (N = 57). Data represent the mean ± SD. P-values shown in bold are significant at the 0.05 level. HSCT hematopoietic stem cell transplantation, BOS bronchiolitis obliterans syndrome, FVC forced vital capacity, FEV1 forced expiratory volume in 1s, RV residual volume, TLC total lung capacity, DLCO carbon monoxide diffusion in the lung
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us